103 related articles for article (PubMed ID: 15266962)
21. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011
[TBL] [Abstract][Full Text] [Related]
22. A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria.
Anand MK; Nelson HS; Dreskin SC
J Allergy Clin Immunol; 2003 May; 111(5):1133-6. PubMed ID: 12743584
[No Abstract] [Full Text] [Related]
23. Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice.
Satyanarayana PS; Jain NK; Singh A; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):641-9. PubMed ID: 15276689
[TBL] [Abstract][Full Text] [Related]
24. Constituents of the seeds of Hernandia ovigera with inhibitory activity against cyclooxygenase-2.
Jang DS; Cuendet M; Su BN; Totura S; Riswan S; Fong HH; Pezzuto JM; Kinghorn AD
Planta Med; 2004 Oct; 70(10):893-6. PubMed ID: 15490314
[TBL] [Abstract][Full Text] [Related]
25. Is the dose to inhibit the COX-2 enzyme in nude mice also adequate in 'human' endometrial tissues?
Matsuzaki S; Canis M
Hum Reprod; 2005 Sep; 20(9):2665; author reply 2665-6. PubMed ID: 16093264
[No Abstract] [Full Text] [Related]
26. Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen.
Levoin N; Blondeau C; Guillaume C; Grandcolas L; Chretien F; Jouzeau JY; Benoit E; Chapleur Y; Netter P; Lapicque F
Biochem Pharmacol; 2004 Nov; 68(10):1957-69. PubMed ID: 15476667
[TBL] [Abstract][Full Text] [Related]
27. Interaction of prostaglandins with the renin-angiotensin system.
Stauss HM
Am J Physiol Regul Integr Comp Physiol; 2003 Apr; 284(4):R1010-1. PubMed ID: 12626362
[No Abstract] [Full Text] [Related]
28. Clinical Vignette. Sciatic nerve entrapment secondary to heterotopic ossification: imaging findings and potential effect of selective cox-2 inhibitors.
Laborde A; Hermier M; Cotton F
Rheumatology (Oxford); 2005 Jan; 44(1):110. PubMed ID: 15611304
[No Abstract] [Full Text] [Related]
29. COX-2-derived prostacyclin confers atheroprotection on female mice.
Egan KM; Lawson JA; Fries S; Koller B; Rader DJ; Smyth EM; Fitzgerald GA
Science; 2004 Dec; 306(5703):1954-7. PubMed ID: 15550624
[TBL] [Abstract][Full Text] [Related]
30. Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ.
Altundag K
J Clin Oncol; 2005 Jul; 23(19):4469-70. PubMed ID: 15994163
[No Abstract] [Full Text] [Related]
31. COX2-alternatives and GI protection.
Med Lett Drugs Ther; 2004 Nov; 46(1195):91-2. PubMed ID: 15534567
[No Abstract] [Full Text] [Related]
32. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
33. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
34. Progress in the treatment of rheumatic disease.
Gause A
Nephrol Dial Transplant; 2003 Jan; 18(1):13-6. PubMed ID: 12480952
[No Abstract] [Full Text] [Related]
35. Involvement of cyclooxygenase-2 and EP3 prostaglandin receptor in acute herpetic but not postherpetic pain in mice.
Takasaki I; Nojima H; Shiraki K; Sugimoto Y; Ichikawa A; Ushikubi F; Narumiya S; Kuraishi Y
Neuropharmacology; 2005 Sep; 49(3):283-92. PubMed ID: 15925391
[TBL] [Abstract][Full Text] [Related]
36. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
37. [Cylooxgenase-2: a novel molecular target for the prevention and treatment of head and neck cancer on the advance of basic and preclinical research].
Guo W; Zeng QH; Wang CY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 May; 39(3):261-3. PubMed ID: 15196405
[No Abstract] [Full Text] [Related]
38. 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.
Biava M; Porretta GC; Cappelli A; Vomero S; Manetti F; Botta M; Sautebin L; Rossi A; Makovec F; Anzini M
J Med Chem; 2005 May; 48(9):3428-32. PubMed ID: 15857149
[TBL] [Abstract][Full Text] [Related]
39. A cyclooxygenase (COX) inhibitory biflavonoid from the seeds of Semecarpus anacardium.
Selvam C; Jachak SM
J Ethnopharmacol; 2004 Dec; 95(2-3):209-12. PubMed ID: 15507338
[TBL] [Abstract][Full Text] [Related]
40. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
